{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:30:45Z","timestamp":1790800245006,"version":"4.1.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":512,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hypertrophic cardiomyopathy (HCM) due to thick filament variants is more common; however, HCM due to thin filament variants (HCM-Thin) may be associated with a more malignant phenotype with an increased risk of sudden cardiac death. The aim of this study was to review all the published cases of HCM-Thin to better understand the natural history and clinical outcomes of this disease. A literature review of HCM-Thin identified 21 studies with a total of 177 patients that were suitable for analysis. There were three outcomes of interest, which included a heart failure composite, a ventricular arrhythmia composite and a heart failure and arrhythmia composite outcome. Kaplan\u2013Meier (KM) survival analyses for freedom from each of the abovementioned composite outcomes were completed for the entire cohort and stratified by age of onset and sarcomeric variant. The heart failure composite occurred in 24 (13.6%) patients, the ventricular arrhythmia composite occurred in 30 patients (16.9%) and the combined heart failure and arrhythmia composite occurred in 50 patients (28.2%). In regard to left ventricular ejection fraction (LVEF), the majority of patients were preserved (LVEF &amp;gt; 50%) compared with mildly reduced (LVEF 41%\u201350%) and reduced (LVEF \u2264 40%) (respectively 26.6% vs. 0.6% vs. 3.4%). The median maximal left ventricular wall thickness (LVWT) was 19.0 mm [interquartile range (IQR) 5.3]. Only 10.7% of the cohort had evidence of left ventricular outflow tract (LVOT) obstruction. Those with paediatric-onset HCM had earlier onset and were at higher risk for each endpoint than their adult counterparts. When stratified by genetic variant, patients with TNNI3 and TPM1 were at a higher risk of the heart failure composite endpoint and the combined heart failure and arrhythmia composite endpoint in comparison with those with the other genetic variants. HCM-Thin is associated with significant morbidity and mortality, with a high arrhythmia burden despite low rates of cardiac obstruction and mild hypertrophy. The paediatric onset of disease and certain sarcomeric variants appear to be associated with a worse prognosis than their adult-onset and other sarcomeric variant counterparts. HCM-Thin seems to have a distinct phenotype, which may require a different management approach.<\/jats:p>","DOI":"10.1002\/ehf2.14848","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T02:28:59Z","timestamp":1716344939000},"page":"3501-3510","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Natural History and Clinical Outcomes of Patients with Hypertrophic Cardiomyopathy from Thin Filament Mutations"],"prefix":"10.1093","volume":"11","author":[{"given":"Tatiana","family":"Saul","sequence":"first","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Medicine, University of California, San Diego , San Diego, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan M.","family":"Bui","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Medicine, University of California, San Diego , San Diego, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Argiro","sequence":"additional","affiliation":[{"name":"Cardiomyopathy Unit, Careggi University Hospital , Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Keyt","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Medicine, University of California, San Diego , San Diego, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iacopo","family":"Olivotto","sequence":"additional","affiliation":[{"name":"Cardiomyopathy Unit, Careggi University Hospital , Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Adler","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Medicine, University of California, San Diego , San Diego, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,21]]},"reference":[{"key":"2026012113120842800_ehf214848-bib-0001","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1161\/01.cir.29.5s4.iv-3","article-title":"Idiopathic hypertrophic subaortic stenosis. I. A description of the disease based upon an analysis of 64 patients","volume":"30","author":"Braunwald","year":"1964","journal-title":"Circulation"},{"key":"2026012113120842800_ehf214848-bib-0002","first-page":"1725","volume-title":"The Heart Arteries and Veins","author":"Towbin","year":"1994","edition":"8th ed."},{"key":"2026012113120842800_ehf214848-bib-0003","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1161\/01.CIR.92.4.785","article-title":"Prevalence of hypertrophic cardiomyopathy in a general population of young adults: Echocardiographic analysis of 4111 subjects in the CARDIA study","volume":"92","author":"Maron","year":"1995","journal-title":"Circulation"},{"key":"2026012113120842800_ehf214848-bib-0004","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1161\/01.CIR.65.7.1388","article-title":"Sudden death in hypertrophic cardiomyopathy: A profile of 78 patients","volume":"65","author":"Maron","year":"1982","journal-title":"Circulation"},{"key":"2026012113120842800_ehf214848-bib-0005","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1161\/01.CIR.80.3.564","article-title":"Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population-based study in Olmsted County, Minnesota, 1975\u20131984","volume":"80","author":"Codd","year":"1989","journal-title":"Circulation"},{"key":"2026012113120842800_ehf214848-bib-0006","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/hrt.20.1.1","article-title":"Asymmetrical hypertrophy of the heart in young adults","volume":"20","author":"Teare","year":"1958","journal-title":"Br Heart J"},{"key":"2026012113120842800_ehf214848-bib-0007","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur Heart J"},{"key":"2026012113120842800_ehf214848-bib-0008","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/S0025-6196(11)60890-2","article-title":"Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy","volume":"83","author":"Olivotto","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"2026012113120842800_ehf214848-bib-0009","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1161\/hc3701.095952","article-title":"Hypertrophic cardiomyopathy: Histopathological features of sudden death in cardiac troponin T disease","volume":"104","author":"Varnava","year":"2001","journal-title":"Circulation"},{"key":"2026012113120842800_ehf214848-bib-0010","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1056\/NEJM199504203321603","article-title":"Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy","volume":"332","author":"Watkins","year":"1995","journal-title":"N Engl J Med"},{"key":"2026012113120842800_ehf214848-bib-0011","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1161\/CIRCRESAHA.110.224170","article-title":"Thin filament mutations: Developing an integrative approach to a complex disorder","volume":"108","author":"Tardiff","year":"2011","journal-title":"Circ Res"},{"key":"2026012113120842800_ehf214848-bib-0012","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1074\/jbc.275.1.624","article-title":"Altered regulation of cardiac muscle contraction by troponin T mutations that cause familial hypertrophic cardiomyopathy","volume":"275","author":"Szczesna","year":"2000","journal-title":"J Biol Chem"},{"key":"2026012113120842800_ehf214848-bib-0013","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/0092-8674(94)90054-X","article-title":"Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: A disease of the sarcomere","volume":"77","author":"Thierfelder","year":"1994","journal-title":"Cell"},{"key":"2026012113120842800_ehf214848-bib-0014","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1016\/j.jacc.2014.09.059","article-title":"Clinical phenotype and outcome of hypertrophic cardiomyopathy associated with thin-filament gene mutations","volume":"64","author":"Coppini","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026012113120842800_ehf214848-bib-0015","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1016\/j.jacc.2014.10.007","article-title":"Thin-filament mutations, hypertrophic cardiomyopathy, and risk","volume":"64","author":"Sherrid","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026012113120842800_ehf214848-bib-0016","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/s0735-1097(96)00530-x","article-title":"Sudden death due to troponin T mutations","volume":"29","author":"Moolman","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"2026012113120842800_ehf214848-bib-0017","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1093\/eurheartj\/ehab148","article-title":"Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy","volume":"42","author":"Marston","year":"2021","journal-title":"Eur Heart J"},{"key":"2026012113120842800_ehf214848-bib-0018","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s11886-020-1260-3","article-title":"Second hits in dilated cardiomyopathy","volume":"22","author":"Marstrand","year":"2020","journal-title":"Curr Cardiol Rep"},{"key":"2026012113120842800_ehf214848-bib-0019","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","article-title":"Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe)","volume":"138","author":"Ho","year":"2018","journal-title":"Circulation"},{"key":"2026012113120842800_ehf214848-bib-0020","doi-asserted-by":"publisher","first-page":"e533","DOI":"10.1161\/CIR.0000000000000938","article-title":"2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: Executive summary: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"142","author":"Ommen","year":"2020","journal-title":"Circulation"},{"key":"2026012113120842800_ehf214848-bib-0021","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1001\/jamacardio.2018.0789","article-title":"Long-term outcomes of pediatric-onset hypertrophic cardiomyopathy and age-specific risk factors for lethal arrhythmic events","volume":"3","author":"Maurizi","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2026012113120842800_ehf214848-bib-0022","doi-asserted-by":"publisher","first-page":"H614","DOI":"10.1152\/ajpheart.01143.2008","article-title":"Temporal and mutation-specific alterations in Ca2+ homeostasis differentially determine the progression of cTnT-related cardiomyopathies in murine models","volume":"297","author":"Guinto","year":"2009","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026012113120842800_ehf214848-bib-0023","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s10741-005-5253-5","article-title":"Sarcomeric proteins and familial hypertrophic cardiomyopathy: Linking mutations in structural proteins to complex cardiovascular phenotypes","volume":"10","author":"Tardiff","year":"2005","journal-title":"Heart Fail Rev"},{"key":"2026012113120842800_ehf214848-bib-0024","doi-asserted-by":"publisher","first-page":"H715","DOI":"10.1152\/ajpheart.00023.2020","article-title":"Mavacamten rescues increased myofilament calcium sensitivity and dysregulation of Ca2+ flux caused by thin filament hypertrophic cardiomyopathy mutations","volume":"318","author":"Sparrow","year":"2020","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026012113120842800_ehf214848-bib-0025","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"2026012113120842800_ehf214848-bib-0026","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1161\/CIRCRESAHA.119.313569","article-title":"Novel therapies for prevention and early treatment of cardiomyopathies","volume":"124","author":"Repetti","year":"2019","journal-title":"Circ Res"},{"key":"2026012113120842800_ehf214848-bib-0027","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ijcard.2019.01.020","article-title":"Danon disease: Gender differences in presentation and outcomes","volume":"286","author":"Brambatti","year":"2019","journal-title":"Int J Cardiol"},{"key":"2026012113120842800_ehf214848-bib-0028","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1097\/GIM.0b013e31820ad795","article-title":"Natural history of Danon disease","volume":"13","author":"Boucek","year":"2011","journal-title":"Genet Med"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/11\/6\/3501\/64516833\/eschf_11_6_3501.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/11\/6\/3501\/64516833\/eschf_11_6_3501.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:14:09Z","timestamp":1769019249000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/11\/6\/3501\/8269362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,21]]},"references-count":28,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,5,21]]},"published-print":{"date-parts":[[2024,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14848","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,5,21]]},"assertion":[{"value":"2023-11-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}